TYRA 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-04

• SURF302 for IR NMIBC: This open-label Phase 2 clinical trial is evaluating the efficacy and safety of oral dabogratinib at 50 mg and 60 mg QD in participants with FGFR3-altered low-grade IR NMIBC, where approximately 70% of tumors are driven by FGFR3. The Company expects to report initial results fr…

• The following table summarizes our results of operations for the periods indicated (in thousands):

• The following table summarizes our research and development expenses by development program for the periods indicated (in thousands):

• Research and development expenses were $72.7 million and $49.3 million for the six months ended June 30, 2026 and 2025, respectively. The $23.4 million increase was primarily driven by a $12.3 million increase in external costs, including a $14.2 million increase related to dabogratinib development …

• General and administrative expenses were $18.3 million and $14.0 million for the six months ended June 30, 2026 and 2025, respectively. The increase of $4.3 million was primarily related to higher compensation and other personnel expenses, including an increase in non-cash stock-based compensation c…

相对上期删除的文字 · 来源:10-Q · 2026-05-13

• We demonstrated initial clinical proof-of-concept results with oral dabogratinib in the SURF301 study, a Phase 1 proof-of-concept study in metastatic urothelial carcinoma (mUC). Oral dabogratinib demonstrated encouraging anti-tumor activity and was generally well-tolerated, with infrequent FGFR2- an…

• SURF302 for IR NMIBC: This open-label Phase 2 clinical trial is evaluating the efficacy and safety of oral dabogratinib at 50 mg and 60 mg QD in participants with FGFR3-altered low-grade IR NMIBC, where approximately 70% of tumors are driven by FGFR3. To date, there are more than 20 patients enrolle…

• Comparison of the Three Months Ended March 31, 2026 and 2025

• On May 8, 2025, we entered into a sales agreement (the 2025 Sales Agreement) with TD Securities (USA) LLC (Sales Agent), under which we may, from time to time, sell shares of our common stock having an aggregate offering price of up to $150.0 million in at-the-market offerings through the Sales Agen…

• The increase of $7.1 million in net cash used in operating activities for the three months ended March 31, 2026, compared to the same period in 2025, was primarily due to an increase of $11.2 million in net loss, offset by changes in operating assets and liabilities of $1.9 million, increases of $1.…

相对上期新增的文字 · 来源:10-Q · 2026-08-04

• (1) Refers to a sell-to-cover instruction letter intended to comply with the requirements of Rule 10b5-1(c) authorizing the pre-arranged sale of shares of our common stock to satisfy tax withholding obligations of the Company arising from the vesting of any restricted stock units (RSUs) and performa…

• (2) The expiration date relating to each instruction letter is dependent on future events which cannot be known at this time, including the final vesting date of the applicable RSUs and PSUs and the officer or director’s termination of service.

• On August 4, 2026, we entered into an amendment to the 2025 Sales Agreement (the Sales Agreement Amendment) with the Sales Agent (the 2025 Sales Agreement, as amended by the Sales Agreement Amendment, the Amended Sales Agreement) increasing the maximum aggregate offering price for shares of our comm…